59 research outputs found
åºä¹³é¡çŽ°èã®HIãã¹ãã³ãªã³é žåé µçŽ ã®ç²Ÿè£œãšãã®æŽ»æ§å¶åŸ¡æ©æ§
é沢倧åŠè¬åŠéšããŠã¹åé€çŽ°èFM3A现èããã¡ããŠH1ãã¹ãã³çé
žåé
µçŽ ããåè£æã«ãããH1ãã¹ãã³çé
žåéšäœãå«ãåæãããã(S1ãããã)ãåºè³ªã«ãæ žç»åããç¡«å®æ²æŸ±ãMonoQãããããã·ã¢ãã¿ã€ããã¹-ã-ã-ã¹12ãMonoSã«ãã£ãŠç²Ÿè£œããããã®çµæããã®é
µçŽ ã¯é
µæ¯ã®CD2^+ãã-ãŒã®åºä¹³é¡åcdc2ãã-ãŒãšåäžã§ããããšãå
ç«ååŠçææ³ã«ããæããã«ãªã£ããããã«ãã®é
µçŽ ã¯H1ãã¹ãã³ã«å¯Ÿãéåžžã«éžææ§ãé«ããåçš®ããããåºè³ªãçšããçµæããããã¬ãªãã³(ã»ãªã³)ãŒãããªã³ãŒ(ã¢ããé
ž)ãŒãªãžã³ã®é
åãèªèããããšãããã£ããH1ãã¹ãã³çé
žåé
µçŽ /cdc2ãã-ãŒã¯çŽ°èåšæã«ãããŠG2/Mæã§æŽ»æ§ãäžæããã®æŽ»æ§ã®äžæã¯é
µçŽ ã®çé
žåããã·ã³æ®åºã®è±çé
žåã䌎ã£ãŠãããã®ãšèãããããããããã®cdc2ãã-ãŒã®G2æã§ã®æŽ»æ§åãMæã§ã®äžæŽ»æ§åãããããã©ã¹ãã¡ã¿-ãŒ1ã2Aã®é»å®³å€ãªã«ãé
žã«ãã£ãŠãããããšããããã掻æ§åãäžæŽ»æ§åãããã®å¶åŸ¡æ©æ§ã«ãããŠãèçœè³ªã®çé
žååå¿ãé¢äžããŠãããã®ãšèããããããã®æ©æ§ã®è©³çŽ°ã«ã€ããŠã¯ä»åŸã®ç 究ãå¿
èŠã§ãããããã«G2/Mæã«é«æž©ã§å¢æ®ãåæ¢ããããŠã¹æž©åºŠæåæ§å€ç°æ ªtsFT210现èãcdc2ãã-ãŒéºäŒåã«ç¹çªç¶å€ç°ããããããã«ããCæ«ç«¯éšã®ãããªã³ãã»ãªã³ã«å€åããŠããããšãã確èªããããã®ããšããåºä¹³é¡çŽ°èã«ãããŠcdc2ãã-ãŒãG2/Mæã«å¿
é ãªé
µçŽ ã§ããããšãæããã«ãããThe H1 histone kinase was purified from mouse mammary carcinoma cell line FM3A cells by use of several steps including ammonium sulfate precipitation, mono Q, hydroxylapatite, superose 12 and mono S coulumn chromatography. The-S1 peptide which contained the sequence of H1 histone phosphorylated at mitosis, was used as substrate. The purified enzyme was the same one as murine homolog to yeast CDC2^+ kinase. This was proven by immunological methods. This H1 histone/cdc2 kinase could phosphorylate specifically H1 histone and recognized Thr(Ser)-Pro-X-Lys sequence, that was proven by use of several synthetic peptides. The activity of H1 histone/cdc2 kinase was increased at G2/M phase and the activation was seemed to be regulated by the dephophorylation of the phosphorylated tyrosine residue of it. Furthermore, Okadaic acid, which was potent inhibitor of phophatase 1 and 2A, could activated the cdc2 kinase in vivo at G1/S and S phase, and it could inactivate same kinase in vivo at mitosis. This suggest that both activation and inactivation of this enzyme are requlated by the protein phosphorylation cascade. Next, it was proven that cdc2 kinase was necessary enzyme for the cells to enter mitosis by use of temperature sensitive mutant tsFT210 cells. The tsFT210 cells could grow at 33^ïŸC but could not grow at 390C. The cells were arrested at G2/M phase at 39^ïŸC.The activity of cdc2 kinase in vitro was temperature sensitive, compared to wild type enzyme. The the cDNA of cdc2 kinase was amplified by PCR method, and sequenced. One point mutation, C to T Change, was found in this mutant at the 905th base from the initial A in ATG codon. This mutation caused a change of proline to serine in the carboxyl teminal region of this enzyme. The wild type cDNA could compensate the temperature sensitivity of this mutant by the transfection into the mutant, it was clear that the mutant cells could not enter nitosis because of the defect of cdc2 kinase.ç 究課é¡/é åçªå·:01571200, ç 究æé(幎床):1989 â 1990åºå
žïŒç 究課é¡ãåºä¹³é¡çŽ°èã®HIãã¹ãã³ãªã³é
žåé
µçŽ ã®ç²Ÿè£œãšãã®æŽ»æ§å¶åŸ¡æ©æ§ã課é¡çªå·01571200ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒ ïŒhttps://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-01571200/015712001990kenkyu_seika_hokoku_gaiyo/ïŒãå å·¥ããŠäœ
æè²äœåçž®å¶åŸ¡ã«ãããcdc2ãã-ãŒã®åœ¹å²
é沢倧åŠè¬åŠéšcdc2ãã-ãŒã¯åºä¹³é¡çŽ°èã«ãããŠåè£æã«ãããæè²äœåçž®ã«éèŠãªåœ¹å²ãæãããŠãããšèããããŠãããä»å¹ŽåºŠã¯ãã®æè²äœåçž®ãé«æž©ã§ããããªãããŠã¹æž©åºŠæåæ§å€ç°æ ªtsFT210现èã®è§£æã«ãããªã£ãããã®çŽ°èã¯é«æž©ã§ã¯G2æã®åæ¢ç¹ããã¡æè²äœåçž®ãããããªãã£ããcdc2ãã-ãŒæŽ»æ§ã調ã¹ããšãããå€ç°çŽ°èã®é
µçŽ ã¯éçæ ªã®é
µçŽ ã«æ¯ã¹ãŠæž©åºŠæåæ§ã§ãã£ããããã§ãã®å€ç°çŽ°èã®cdc2ãã-ãŒcDNAãPCRæ³ã§å¢å¹
ããå¡©åºé
åãéçæ ªã®ãã®ãšæ¯èŒãããšããéå§ã³ãã³ãã905çªç®ã®å¡©åºCãå€ç°çŽ°èã§ã¯Tã«å€åãããã®çµæã¢ããé
žã®ãããªã³ãã»ãªã³ã«å€åããŠãããããã«éçæ ªã®cDNAãå€ç°çŽ°èã«ç§»å
¥ãããšå€ç°çŽ°èã®æž©åºŠæåæ§ãçžè£ãããã以äžã®ããšãããã®tsFT210现èã¯cdc2ãã-ãŒã枩床æåæ§ã§ããããã«G2æã®é«æž©ã§åæ¢ããããšãèããããcdc2ãã-ãŒãåè£æã«ãããæè²äœåçž®ã«å¿
é ãªãã®ãšã®ç¥èŠãåŸããããããã«ãã®cdc2ãã-ãŒæŽ»æ§ãå¶åŸ¡ããŠããå åã®æ€èšããããªã£ããåè£æã§ã®cdc2ãã-ãŒã®æŽ»æ§åã¯çé
žåããã·ã³åºã®è±çé
žåã«ãããšèãããããããã«cdc2ãã-ãŒãšçµåãããµã€ã¯ãªã³èçœè³ªããã®é
µçŽ 掻æ§ã«åœ±é¿ãäžããŠãããšèããããçµåãããµã€ã¯ãªã³ã®çš®é¡ã«ãã£ãŠcdc2ãã-ãŒãåé¢ãããšãããµã€ã¯ãªã³Açµåäœãšããã¯ãªã³Bçµéäœã§H1ãã¹ãã³ã«å¯Ÿãã芪åæ§ã倧ããéã£ãŠããããšã確èªãããããã®åºè³ªã«å¯Ÿãã芪åæ§ã®å€åã现èå
ã«ãããcdc2ãã-ãŒã®åºè³ªã®å€åã«å¯Ÿå¿ããŠããå¯èœæ§ãé«ããšæããããç 究課é¡/é åçªå·:02260203, ç 究æé(幎床):1990åºå
žïŒç 究課é¡ãæè²äœåçž®å¶åŸ¡ã«ãããcdc2ãã-ãŒã®åœ¹å²ã課é¡çªå·02260203ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒ ïŒhttps://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-02260203/ïŒãå å·¥ããŠäœ
DNAè€è£œå¶åŸ¡ã«ããããµã€ã¯ãªã³äŸåæ§ãããŒãŒ(cdk)ã®åœ¹å²
é沢倧åŠè¬åŠéšåè£é
µæ¯ã®weelå€ç°ãçžè£ã§ããããweeléºäŒåç£ç©ã倧è
žèå
ã§çºçŸç²Ÿè£œãããã®é
µçŽ 掻æ§ãæ€èšããããã®çµæããweelãããŒãŒã¯ãµã€ã¯ãªã³B/cdc2ãããŒãŒã®Tyr-15ãçé
žåããã®æŽ»æ§ãé»å®³ããããšãæããã«ãããããããã®é
µçŽ ã¯Thr-14ãçé
žåã§ããªãã£ãããã®ããšã¯Thr-14ãçé
žåãp34^ãããŒãŒæŽ»æ§ãé»å®³ããæ°ããªãããŒãŒãååšããããšã瀺åããŠãããäžæ¹ã3çš®ã®ããcdc25ãã©ã¹ãã¡ã¿ãŒãŒã倧è
žèå
ã§çºçŸããããããé
µçŽ ã®æŽ»æ§ãæ€èšãããåèšããp34^ãããŒãŒã®çé
žåã«ãã掻æ§é»å®³ã¯ãã®ããcdc25ãã©ã¹ãã¡ãŒã¿ãŒãŒã«ããå埩ããã3çš®ååšããããcdc25ãã©ã¹ãã¡ã¿ãŒãŒã®ãã¡å°ãªããšãcdc25Bã¯ãã®Tyr-15ã®ã¿ãªããThr-14ã®çé
žåºãè±çé
žåãããã®æŽ»æ§ãäžæããããããã«cdk2ã®æŽ»æ§å¶åŸ¡ã«é¢é£ããŠãã®é
žçŽ ã®çé
žåéšäœãæ€èšãããšããTyr-15ãšThr-160ã確èªãããããã®Thr-160ãçé
žåããããšSDSé»æ°æ³³åã§ç§»å床ãéããªããããã¯èçœè³ªãp34^ãããŒãŒãå«ããäžè¬ã«ãçé
žåããããšç§»å床ãé
ããªãçŸè±¡ãšã¯ç°ãªãããµã€ã¯ãªã³Açµåcdk2ã¯ãã®Thr-160ã®çé
žåäœã§ãã£ãããšããããµã€ã¯ãªã³çµåã«ã¯ãã®Thr-160ã®çé
žåãå¿
èŠã§ãããšèããããããµã€ã¯ãªã³A/cdk2ã®Tyr-15ã®çé
žã¯ããCDC25ãã©ã¹ãã¡ã¿ãŒãŒã§ã¯ãµã€ã¯ãªã³B/cdc2ãããŒãŒã®ããã«ã¯å¹çããè±çé
žåãããããã®åå ããµã€ã¯ãªã³èçœè³ªã®éãã«ããã®ãã©ãããTyr-15ã®çççæå³ãå«ããŠèå³æ·±ããç 究課é¡/é åçªå·:04256211, ç 究æé(幎床):1992åºå
žïŒç 究課é¡ãDNAè€è£œå¶åŸ¡ã«ããããµã€ã¯ãªã³äŸåæ§ãããŒãŒ(cdk)ã®åœ¹å²ã課é¡çªå·04256211ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒ ïŒhttps://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-04256211/ïŒãå å·¥ããŠäœ
ã¢ãã¯ããŒãã«æäœããã¡ãã,HIãã¹ãã³ã®ã¯ãããã³æ§é ã®èª¿ç¯ã«é¢ããç 究
é沢倧è¬åŠéšHIãã¹ãã³ã®ã¯ãããã³æ§é ã®èª¿ç¯ã«ããã圹å²ãç 究ããçºã«ãHIãã¹ãã³å°æåã«å¯Ÿããã¢ãã¯ããŒãã«æäœã®äœè£œãè©Šã¿ããHIãã¹ãã³å°æåã®åé¢ã¯ã©ããèããå
šHIãã¹ãã³ã5%éå¡©çŽ é
žã§æœåºãããããé«é液äœã¯ãããã°ã©ãã£ãŒC18éçžã«ã©ã ã§ãªã³é
ž-éãšãŠçŽ é
žãããªãŠã ååšäžã¢ã»ããããªã«41%ãã44%ã®äžæéã®çŽç·æ¿åºŠåŸé
ã«ãã溶åºãåé¢ããããããŸã§éœã€ãªã³äº€ææš¹èBio Rex70ã§äžé±éãããŠããå°æåã®çžäºåé¢ãäžæéã§çµäºããããšãèãããšããã®é«é液äœã¯ãããã°ã©ãã£ãŒãçšããæ¹æ³ã®æçšæ§ã¯æããã§ãããã¢ãã¯ããŒãã«æäœã®äœè£œã¯Balb/cããŠã¹ãHIãã¹ãã³ã§å
ç«ããããšã«ããåžžæ³éãè¡ãªã£ããããŠã¹ããšããŒã现èãšããŠã¯ãNS1ãP3U1现èãçšããããªãšãã¬ã³ã°ãªã³ãŒã«ã§æäœèŸçŽ°èãšèåãããåŸãããHIæäœç£çã¯ããŒã³48ã±ã®ãã¡1ã¯ãŒãã³ã2ã»1C2ã«ã€ããŠè©³çŽ°ãªæ€èšãå ããã2.1C2ã®ç£çããæäœã¯ÎgMã§ããããã®æäœã¯ãã¹ãŠã®HIãã¹ãã³å°æåãšåå¿æ§ã瀺ãããããã§ãã®æäœèªèéšäœãæ€èšãããHIãã¹ãã³ã¯äžå€®ã®çæ°Žæ§éš(ããã)ãNæ«åŽ(ããŒãº)ãCæ«åŽ(ããŒã«)ã®3éšäœã«æ§é äžåé¡ããããåã
ã®éšäœãããªãã·ã³ããã¢ããªãã·ã³ãããã³ãã³ã«ããHIãã¹ãã³ã®éå®å解ã«ããåŸããŠã§ã¹ã¿ã³ããããã£ã³ã°ãé
µçŽ å
ç«æ³ã«ããæäœã®åå¿æ§ã調ã¹ããšããHIãã¹ãã³ã®çæ°Žæ§éšã®Cæ«ç«¯åŽã®ã€ãæ ¹éšåã§ããããšãæããã«ãªã£ããããªãã¡ããã®éšåãHIãã¹ãã³å°æåã®ãã¹ãŠã«å
±éãªæå決å®åºã§ãããHIã®çæ°Žæ§éšãDNAãšHIãã¹ãã³ã®çµåã«é¢äžããŠããããšããèãåããããšãçæ°Žæ§éšã«é£æ¥ããCæ«ç«¯åŽã®äžå®ã®æ§é ãHIãã¹ãã³ã®ã¯ãããã³äžã§ã®çµåã«éèŠãªã®ã§ããããšèãããããç 究課é¡/é åçªå·:61571047, ç 究æé(幎床):1986åºå
žïŒç 究課é¡ãã¢ãã¯ããŒãã«æäœããã¡ãã,HIãã¹ãã³ã®ã¯ãããã³æ§é ã®èª¿ç¯ã«é¢ããç 究ã課é¡çªå·61571047ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒ ïŒhttps://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-61571047/ïŒãå å·¥ããŠäœ
G_0æã«ç¹ç°çã«çºçŸãããH1ãã¹ãã³éºäŒåã®ã¯ããŒãã³ã°ããã³ãã®çºçŸèª¿ç¯
é沢倧åŠè¬åŠéšæ¬ç 究ã§ã¯ãH1ãã¹ãã³å°æåãH1°ãã¹ãã³ã®çžäºåé¢æ³ã確ç«ãããããã®æ§ç¶è§£æãè¡ãªã£ããããã«ã现èå¢æ®ãåçµç¹éãäŒçéçšã«ããããããã®çºçŸã®éããæããã«ããåã
ã®å°æåãŸãã¯H1°ãã¹ãã³ãããããã«ãããŠããã®ãã®ç¹ç°çãªåœ¹å²ãæ
ã£ãŠããããšã匷ã瀺åããçµæãåŸããå
·äœçã«ã¯ãå°æåãH1°ãã¹ãã³ã®çžäºåé¢ã¯ãC18ã«ã©ã ãçšããéçžé«é液äœã¯ãããã°ã©ãã£ãŒ(HPLC)ã§çæéã§å¯èœãšãªãããããçšããŠåé¢ç²Ÿè£œããæšåãããããŠã¹ãã©ãããšã5çš®ã®H1ãã¹ãã³å°æåãšã1åã®H1°ãæã£ãŠããããšãæãããšãªã£ãããŸããããŠã¹ã®çµç¹ã«ãããŠã¯å°æåIVãå
šH1ãã¹ãã³ãH1°ãã¹ãã³éã®40%以äžãããããŸããH1°ãã¹ãã³ã¯èžè
ºãèŸèã§ã¯ãã®ååšã確èªã§ããªãã£ããããŠã¹ã®çåŸã®èæçéçšã«ãããŠãå°æåIãIIãIIIã¯æ¬¡ç¬¬ã«æžå°ããŠããã®ãã¿ããããå°æåIVã®éã¯ã»ãŒå€åããªãå°æåVã®ã¿ã6é±ä»€ã§ãã®éãæ倧ã«éãã以åŸæžå°ããã®ãã¿ããããH1ãã¹ãã³ãH1°ãã¹ãã³ã®ç·éã¯æçéçšã§ã»ãŒäžå®ã§ãããããããå°æåã®æžå°éãè£ãã®ã¯H1°ãã¹ãã³ã®æçéçšã§ã®å¢å ã§ãããšèãããããå®éã«H1°ã®ååšããªãèžè
ºãèŸèã§ã¯å°æåV以å€ã®å°æåã®éã«ã»ãšãã©å€åãã¿ãããªãã£ãã现èåšæã«ãããŠã¯ãG_0æã§ç¹ç°çã«çºçŸãããã®ã¯ãããŠã¹Ba1b/c3T3现èã§ã¯ãIIIãããã³H1°ãã©ããNRK现èã§ã¯ãIIãIIIã§ãã£ã(NRKã§ã¯H1°ã¯ã»ãšãã©ç¢ºèªã§ããªãã£ã)ãå³ã¡ãDNAåæãšçžé¢ããã«åæãããH1°ãå°æåIIIãII(ã©ãã)ãã现èã®æ©èœã®å¶åŸ¡æ©æ§ã«éèŠãªåœ¹å²ãæãããŠãããšèããããããŸãããããã®ç¹ç°ççºçŸã®mRNAã¬ãã«ã§ã®å¶åŸ¡æ©æ§ãç¥ãç®çã§ãã©ããããH1ãã¹ãã³éºäŒåã®ã²ãããã¯ã¯ããŒãã³ã°ãè¡ãªãã1åã®ã¯ããŒã³ãåŸããThe expression of the H1 histone subtypes and H1^o histone in a cell cycle and during maturations of tissues were investigated. At first the method of the separtion of H1 subtypes and H1^o histone each other was developed. The five subtypes of H1 histone and H1^o histone were separated each other by use of reverse phase HPLC(C18-300), using a gradient of acetonitrile. Then, the subtypes of H1 histone and H1^o histone in tissues of mouse were investigated by use of this method. The subtype IV was more than 40% of total H1 histones in most of the tissues investigated, including liver, lung, cerebrum, heart, kidney and cerebellum. There were detected no H1^o histone in thymus and spleen. The amounts of subtypes of H1 histone during maturation of liver, changed. Subtypes I,II and III, were decreased gradually during maturation. The amount of subtype IV was almost constant during maturation. The amount of subtype V reached maximum 6 week after birth and decreased gradually. Only H1^o histone was increased during the maturation. The increase in this amount could compensate the decrease in the amounts of H1 subtypes during the maturation. The amounts of subtypes of thymus and spleen did not change during the maturation. This evidence was coincident with the evidence that there was no H1^o histone in thymus and spleen. In a cell cycle of mouse Balb/c 3T3 cells, the syntheses of H1^o histone and subtype III were detected at G0 phase. The syntheses of other subtypes occurred during S Phase. Furthermore, the H1 histone genomic DNA was cloned from rat genomic DNA library. It must be very useful to investigate the regulation of the H1 gene expression during a cell cycle traverse.ç 究課é¡/é åçªå·:62570981, ç 究æé(幎床):1987 â 1988åºå
žïŒç 究課é¡ãG_0æã«ç¹ç°çã«çºçŸãããH1ãã¹ãã³éºäŒåã®ã¯ããŒãã³ã°ããã³ãã®çºçŸèª¿ç¯ã課é¡çªå·62570981ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒ ïŒhttps://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-62570981/625709811988kenkyu_seika_hokoku_gaiyo/ïŒãå å·¥ããŠäœ
æ°ãããµã€ã¯ãªã³äŸåæ§ãããŒãŒ(cdk)ã«ãã现èåšæã®å¶åŸ¡æ©æ§ã®è§£æ
é沢倧åŠè¬åŠéšåºä¹³é¡çŽ°èã®å¢æ®å¶åŸ¡æ©æ§ã«ããããµã€ã¯ãªã³äŸåæ§ãããŒãŒã®åœ¹å²ã«é¢é£ãããã®ãããŒãŒã®æŽ»æ§å¶åŸ¡æ©æ§ã«çŠç¹ãããŠãããµã€ã¯ãªã³äŸåæ§ãããŒãŒã®ãã¡cdc2ãããŒãŒã¯ãã®æŽ»æ§ãçé
žåã«ããå¶åŸ¡ãããŠããå¯èœæ§ã瀺åãããŠããŠãããåºä¹³é¡çŽ°èã®cdc2ãããŒãŒã®å Žå3ã«æã®çé
žåãå³ã¡Næ«ãã14çªç®ã®ãã¬ãªãã³æ®åº(14-T)ã15çªç®ã®ããã·ã³æ®åº(15-Y)ã161çªç®ã®ãã¬ãªãã³æ®åº(161-T)ã®çé
žåãããã®æŽ»æ§å¶åŸ¡ã«å¯äžããŠãããšèããããŠãããããã§ãããã®éšäœãçé
žé
žåãè±çé
žåããé
µçŽ ãæ€èšãããåè£é
µæ¯ã®weelå€ç°ãçžè£ããéºäŒåããweeléºäŒåç£ç©ã倧è
žèã§çºçŸãããã®æŽ»æ§ãæ€èšããããã®çµæãã®å€§è
žèçºçŸããweelç£ç©ã¯ããã·ã³ãããŒãŒã§ããcdc2ãããŒãŒã®15-Yãçé
žåããé
µçŽ ã§ããããšãæããšãªã£ããé
µæ¯ã®åè£æé²è¡ã®å€ç°cdc25ãçžè£ããéºäŒåããcdc25éºäŒåã¯ãã®15-Yãè±çé
žåããé
µçŽ éºäŒåãšããŠæåŸ
ããããå®éãã®ããcdc25BéºäŒåç£ç©ã倧è
žèã§çºçŸãããã®è±çé
žåé
µçŽ 掻æ§ã調ã¹ããšãã®é
µçŽ ã¯çé
žåcdc2ãããŒãŒã»ãµã€ã¯ãªã³Bè€åäœãè±çé
žåãé
µçŽ 掻æ§ãå埩ãããããã®æãã®é
µçŽ ã¯çé
žå14-Tã15-Yã161-Tã®ãã¡14-Tã15-Yãè±çé
žåãããããŒãŒæŽ»æ§ãå埩ãããã161-Tã¯è±çé
žåããªãã£ããå³ã¡ããcdc25BéºäŒåç£ç©ã¯cdc2ãããŒãŒãè±çé
žåããããšã«ãã£ãŠæŽ»æ§åãããã¬ãªãã³ãããã·ã³ãã¹ãã¡ã¿ãŒãŒã§ããããããåºè³ªç¹ç°æ§ãé«ããã®ã§ããããšãæããšãªã£ãã161-Tã®çé
žåã¯äžèšããããšããããããããã«é
µçŽ 掻æ§ãäžæŽ»åããããšã¯ãªãã£ããéã«ãã®çé
žåã¯ãã®é
µçŽ ã®æŽ»æ§ã«å¿
é ãªããšãæããšãªãæã
ã¯ãã®åºä¹³é¡ã®é
µçŽ ãšããŠããŠã¹CAK(cyclin dependent kinase activating kinase)éºäŒåãåé¢ãããThe activity of cdc2 kinase is regulated by the phosphorylation and dephosphorylation of its own molecule. The phosphorylation of Thr-14 and/or Tyr-15 inhibits the kinase activity, whereas the phosphorylation of Thr-161 is necessary for the activity of this kinase. We tried to find out the kinase which phosphorylated the cdc2 kinase and inhibited the activity. Human weel kinase had such kind of activity. The kinase could phosphorylate Try-15 of the cdc2 molecule but not do Thr-14. The kinase which could phosphorylate Thr-14 now to be elucidated. The enzyme which phosphorylates this Trh-161 is named CAK(cyclin dependent kinase activating kinase). Recent work revealed Xenopus laevis p40MO15 kinase could phosphorylate this residue and activate the kinase. The DNA sequence of this kinase is homologus to that of R-2 protein which was isolated from rice cells as one of the cdks. We tried to clarify whether this R-2 protein has kinase activity to activate the cdc2 kinase. We found the R-2 kinase, which was produced in E.coli, could activate the HeLa cdc2 kinase in the presence of cyclin B.Also we isolated the mouse homologue of p40MO15. These kinases had NXTALRE sequence in stead of PSTAIRE of cdc2 kinase.ç 究課é¡/é åçªå·:04833008, ç 究æé(幎床):1992 â 1993åºå
žïŒç 究課é¡ãæ°ãããµã€ã¯ãªã³äŸåæ§ãããŒãŒ(cdk)ã«ãã现èåšæã®å¶åŸ¡æ©æ§ã®è§£æã課é¡çªå·04833008ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒ ïŒhttps://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-04833008/048330081993kenkyu_seika_hokoku_gaiyo/ïŒãå å·¥ããŠäœ
Mutant p53 proteins bind DNA in a DNA structure-selective mode
Despite the loss of sequence-specific DNA binding, mutant p53 (mutp53) proteins can induce or repress transcription of mutp53-specific target genes. To date, the molecular basis for transcriptional modulation by mutp53 is not understood, but increasing evidence points to the possibility that specific interactions of mutp53 with DNA play an important role. So far, the lack of a common denominator for mutp53 DNA binding, i.e. the existence of common sequence elements, has hampered further characterization of mutp53 DNA binding. Emanating from our previous discovery that DNA structure is an important determinant of wild-type p53 (wtp53) DNA binding, we analyzed the binding of various mutp53 proteins to oligonucleotides mimicking non-B DNA structures. Using various DNA-binding assays we show that mutp53 proteins bind selectively and with high affinity to non-B DNA. In contrast to sequence-specific and DNA structure-dependent binding of wtp53, mutp53 DNA binding to non-B DNA is solely dependent on the stereo-specific configuration of the DNA, and not on DNA sequence. We propose that DNA structure-selective binding of mutp53 proteins is the basis for the well-documented interaction of mutp53 with MAR elements and for transcriptional activities mediates by mutp53
Regulation of the osteoblast-specific transcription factor Osterix by NO66, a Jumonji family histone demethylase
Osterix (Osx) is an osteoblast-specific transcription factor required for osteoblast differentiation and bone formation. Osx null mice develop a normal cartilage skeleton but fail to form bone and to express osteoblast-specific marker genes. To better understand the control of transcriptional regulation by Osx, we identified Osx-interacting proteins using proteomics approaches. Here, we report that a Jumonji C (JmjC)-domain containing protein, called NO66, directly interacts with Osx and inhibits Osx-mediated promoter activation. The knockdown of NO66 in preosteoblast cells triggered accelerated osteoblast differentiation and mineralization, and markedly stimulated the expression of Osx target genes. A JmjC-dependent histone demethylase activity was exhibited by NO66, which was specific for both H3K4me and H3K36me in vitro and in vivo, and this activity was needed for the regulation of osteoblast-specific promoters. During BMP-2-induced differentiation of preosteoblasts, decreased NO66 occupancy correlates with increased Osx occupancy at Osx-target promoters. Our results indicate that interactions between NO66 and Osx regulate Osx-target genes in osteoblasts by modulating histone methylation states
- âŠ